Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$161,411,749
New position
Shares Held
6,275,729
first reported quarter
Ownership
3.93%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#7
of 290 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026VANGUARD CAPITAL MANAGEMENT LLC holds $43,113,715,765 across 464 Biotechnology names. DNLI ranks #46 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
16,580,713 | $8,236,137,568 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
6,629,759 | $4,133,919,926 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
6,029,478 | $1,815,053,762 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
9,088,661 | $1,702,124,432 | |
| 5 | MRNA |
Moderna, Inc.
|
23,208,792 | $1,625,311,703 | |
| 6 | INCY |
Incyte Corp
|
11,024,289 | $1,249,713,401 | |
| 7 | INSM |
INSMED Inc
|
9,790,865 | $1,043,902,026 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
22,123,198 | $782,939,977 |
All Filings in DNLI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $161,411,749 | 6,275,729 | Shares | Defined | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||